LADENBURG THALM/SH SH reaffirmed their buy rating on shares of Novus Therapeutics (NASDAQ:NVUS) in a research note published on Wednesday, AnalystRatings.com reports. The brokerage currently has a $10.00 price target on the biopharmaceutical company’s stock.

NVUS has been the subject of several other reports. Zacks Investment Research cut Novus Therapeutics from a hold rating to a sell rating in a research report on Saturday, March 30th. ValuEngine raised Novus Therapeutics from a hold rating to a buy rating in a research report on Monday, February 25th.

Shares of NVUS stock traded up $0.03 on Wednesday, hitting $2.23. 100 shares of the stock were exchanged, compared to its average volume of 38,140. The stock has a market capitalization of $20.66 million, a P/E ratio of -1.41 and a beta of 3.32. Novus Therapeutics has a fifty-two week low of $1.52 and a fifty-two week high of $8.61.

Novus Therapeutics (NASDAQ:NVUS) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). As a group, sell-side analysts anticipate that Novus Therapeutics will post -1.81 earnings per share for the current fiscal year.

In related news, Director Erez Chimovits purchased 646,204 shares of Novus Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The stock was purchased at an average cost of $3.10 per share, with a total value of $2,003,232.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Novus Therapeutics by 28.6% in the third quarter. Renaissance Technologies LLC now owns 251,556 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 55,968 shares during the last quarter. National Asset Management Inc. lifted its position in shares of Novus Therapeutics by 32.8% in the first quarter. National Asset Management Inc. now owns 159,705 shares of the biopharmaceutical company’s stock valued at $643,000 after buying an additional 39,486 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Novus Therapeutics by 73.5% in the third quarter. Vanguard Group Inc now owns 135,599 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 57,450 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Novus Therapeutics by 73.5% in the third quarter. Vanguard Group Inc. now owns 135,599 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 57,450 shares during the last quarter. Finally, Morgan Stanley lifted its position in shares of Novus Therapeutics by 5,676.8% in the first quarter. Morgan Stanley now owns 12,189 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 11,978 shares during the last quarter. 36.03% of the stock is owned by institutional investors.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

Further Reading: Debt-To-Equity Ratio

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.